Market Overview

Integra LifeSciences Receives FDA Clearance for Expanded Indication for Spinal Device

Related IART
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed
Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B

Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that the Food and Drug Administration (FDA) has approved an expanded indication for use of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures. The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate™. The Integra® Vu aPOD™ Prime IBD will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in Chicago, Illinois.

Posted-In: News FDA


Related Articles (IART)

View Comments and Join the Discussion!

Get Benzinga's Newsletters